Moderna and Uber say they will work together initially to provide accessible, credible information on vaccine safety through Uber's in-app messaging.
The two companies will also work with public health and other organizations to identify additional opportunities to support ongoing efforts to broaden access to COVID-19 vaccines.
Additional options being evaluated include incorporating ride scheduling directly into the immunization appointment process, and possibly integrating with vaccine providers' systems to text reminders and enable patients to book rides in advance of their first or second immunization appointments.
In December, Uber committed 10 m free or discounted rides to help ensure transportation is not a barrier to getting a vaccine.
Targeting communities hardest hit by the pandemic, Uber partnered with the National Urban League, National Action Network and the Morehouse School of Medicine.
Uber will continue to build a broad coalition of organizations committed to breaking down transportation barriers in these communities.
The Moderna COVID-19 Vaccine has been authorized for emergency use in the US by the FDA for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older and has been authorized by Health Canada for the immunization of Canadians 18 years of age and older under an Interim Order.
The Moderna COVID-19 Vaccine has also been granted a Conditional Marketing Authorization by the European Commission, based upon the recommendation of the European Medicines Agency, which authorizes the COVID-19 Vaccine Moderna for active immunization to prevent COVID-19 caused by SARS-CoV-2 virus in individuals 18 years of age and older.
While initially targeting Uber users in the United States, the companies anticipate expanding this partnership globally in the coming months alongside ongoing immunization efforts.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval